Development of phosphoinositide 3-kinase delta (PI3Kδ) inhibitors as potential anticancer agents through the generation of ligand-based pharmacophores and biological screening

Molecular Properties That Influence the Oral Bioavailability of Drug Candidates

Daniel F. Veber, Stephen R. Johnson, Hung‐Yuan Cheng et al. · Journal of Medicinal Chemistry · 2002 · 8.1K citations

Pharmacy, Pharmacokinetics, Pharmacology +15

Virtual Screening Workflow Development Guided by the “Receiver Operating Characteristic” Curve Approach. Application to High-Throughput Docking on Metabotropic Glutamate Receptor Subtype 4

Nicolas Triballeau, Francine Acher, Isabelle Brabet et al. · Journal of Medicinal Chemistry · 2005 · 621 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +13

Interpreting Steep Dose-Response Curves in Early Inhibitor Discovery

Brian K. Shoichet · Journal of Medicinal Chemistry · 2006 · 298 citations

Life Sciences, Medicinal Chemistry, Pharmacology +14

Next generation 3D pharmacophore modeling

David Schaller, Dora Šribar, Theresa Noonan et al. · Wiley Interdisciplinary Reviews Computational Molecular Science · 2020 · 272 citations · Full text

Pharmacy, Medicinal Chemistry, Drug Design +7

p110δ, a Novel Phosphatidylinositol 3-Kinase Catalytic Subunit That Associates with p85 and Is Expressed Predominantly in Leukocytes

David Chantry, Anne B. Vojtek, Adam Kashishian et al. · Journal of Biological Chemistry · 1997 · 250 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +12